Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Idogen AB's share price for the quarter that ended in Mar. 2023 was kr0.077. Idogen AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2023 was 104.37 Mil. Therefore, Idogen AB's market cap for the quarter that ended in Mar. 2023 was kr8.04 Mil.
Idogen AB's quarterly market cap
declined
from Sep. 2022 (kr22.84 Mil) to Dec. 2022 (kr18.27 Mil) and
declined
from Dec. 2022 (kr18.27 Mil) to Mar. 2023 (kr8.04 Mil).
Idogen AB's annual market cap
declined
from Dec. 2020 (kr55.64 Mil) to Dec. 2021 (kr30.50 Mil) and
declined
from Dec. 2021 (kr30.50 Mil) to Dec. 2022 (kr18.27 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Idogen AB's Enterprise Value for Today is kr9.60 Mil.
Idogen AB (OSTO:IDOGEN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Idogen AB Market Cap Related Terms
Idogen AB Market Cap Historical Data
* Premium members only.
The historical data trend for Idogen AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IDOGEN vs REGN, VRTX, MRNA: Market Cap Comparison
For the Biotechnology subindustry, Idogen AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idogen AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idogen AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Idogen AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Idogen AB's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idogen AB (OSTO:IDOGEN) has a Market Cap of kr12.58 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Idogen AB and its competitors.
Is Idogen AB's Market Cap too high?
Idogen AB's current Market Cap is kr12.58 Mil. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's Market Cap compare to REGN and VRTX?
Idogen AB's Market Cap of kr12.58 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Idogen AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idogen AB's current Market Cap is kr12.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current Market Cap of kr12.58 Mil. The current Market Cap is kr12.58 Mil. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current Market Cap is kr12.58 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score
Get the complete analysis for OSTO:IDOGEN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDOGEN has been successfully added to your 
